Prescribing Information
Important Safety Information
Patient Site
Contact Us

Maintain copper 
balance with CUVRIOR

CUVRIOR (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease (WD) who are de-coppered and tolerant to penicillamine.1

Helps maintain copper balance in adults with stable disease.2

Copper deficiency may develop following treatment with CUVRIOR. Periodic monitoring by a healthcare professional is required.1
Actor portrayal

CUVRIOR offers patients 
on-the-go potential 

CUVRIOR offers convenient twice-daily dosing and is stable at room temperature, so it doesn’t require refrigeration.1

A starting total daily dose of CUVRIOR in adults ranges from 300 mg to 3000 mg orally in divided doses taken just 2 times a day.1

Take CUVRIOR on an empty stomach (at least 1 hour before meals or 2 hours after meals and at least 1 hour apart from any other food, milk, or oral medication).
Learn More

CUVRIOR: BEHIND
THE MYSTERY

This video features Dr Amanda Cheung, Hepatologist; Rhonda Rowland from the Wilson Disease Association; Dr Naseem Amin, Orphalan CEO; and Mandy, CUVRIOR's Patient Ambassador, discussing Wilson Disease, its impact, and how CUVRIOR and the Navigator Program can help.

Explore a switch to CUVRIOR

More than 50% of patients report poor WD treatment adherence, potentially because of frequency of dosing or treatment side effects.3–5

If you are switching your patient to CUVRIOR, 
learn how to convert their current treatment 
to a CUVRIOR dose.
CUVRIOR Dosing Calculator

Get in touch with us

Whether you're requesting more information or requesting a visit from a Key Account Manager or Field Medical Affairs Representative, we look forward to hearing from you!

References

1. CUVRIOR [package insert]. Chicago, IL: Orphalan SA. 2. Schilsky ML, Czlonkowska A, Zuin M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(12):1092-1102. 3. Miloh T, Graper M, Schilsky M. Advances in rare diseases. Evaluating diagnosis and management gaps in wilson disease: results from a qualitative patient survey. Adv Rare Dis. 4:1. 4. Jacquelet E, Poujois A, Pheulpin MC, et al. Adherence to treatment, a challenge even in treatable metabolic rare diseases: a cross sectional study of Wilson’s disease. J Inherit Metab Dis. 2021;44(6):1481-1488. 5. Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428-1455.

Indication & Important Safety Information

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease who are de-coppered and tolerant to penicillamine. Please see full Prescribing Information.
Important Safety Information

INDICATION

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR.

WARNINGS AND PRECAUTIONS

  • Potential for Worsening of Clinical Symptoms at Initiation of Therapy, including neurological deterioration, may occur at the beginning of CUVRIOR therapy due to mobilization of excess stores of copper. Adjust the dosage or discontinue therapy if clinical condition worsens. Evaluate serum non-ceruloplasmin copper (NCC) levels or 24-hour urinary copper excretion (UCE) when initiating treatment, after 3 months, and approximately every 6 months thereafter.
  • Copper Deficiency may develop following treatment with CUVRIOR. Periodic monitoring is required.
  • Iron Deficiency may develop following treatment with CUVRIOR. If iron deficiency develops, a short course of iron supplementation may be given.
  • Hypersensitivity Reactions, characterized by rash, have been reported with the use of trientine. Rash was reported in 12% (3/26) of CUVRIOR-treated patients, and one patient discontinued treatment due to rash. If rash or other hypersensitivity reaction occurs, consider discontinuing CUVRIOR.

ADVERSE REACTIONS

The most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings.

DRUG INTERACTIONS

  • Mineral Supplements (e.g. iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable, take CUVRIOR at least 2 hours before or 2 hours after iron and take CUVRIOR at least 1 hour before or 2 hours after other mineral supplements.
  • Other Drugs for Oral Administration: Take CUVRIOR at least 1 hour apart from any other oral drug.

To report SUSPECTED ADVERSE REACTIONS, contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or 
www.fda.gov/medwatch.

Please see full Prescribing Information.